Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

BACKGROUND: A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically. The Mel-Ipi-Rx phase 1 study aimed to determine the maximum tolerated dose (MTD) and safety profile of radiotherapy combined with ipi...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutros, Celine, Chaput-Gras, Nathalie, Lanoy, Emilie, Larive, Alicia, Mateus, Christine, Routier, Emilie, Sun, Roger, Tao, Yun Gan, Massard, Christophe, Bahleda, Rastilav, Schwob, Dominique, Ibrahim, Nathalie, Khoury Abboud, Rita Maria, Caramella, Caroline, Lancia, Andrea, Cassard, Lydie, Roy, Severine, Soria, J -C, Robert, Caroline, Deutsch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443273/
https://www.ncbi.nlm.nih.gov/pubmed/32819972
http://dx.doi.org/10.1136/jitc-2020-000627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443273/
https://www.ncbi.nlm.nih.gov/pubmed/32819972
http://dx.doi.org/10.1136/jitc-2020-000627

Ejemplares similares